(October 27, 2017, 8:54 AM EDT) -- WASHINGTON, D.C. — A divided Federal Circuit U.S. Court of Appeals on Oct. 26 upheld a Delaware federal judge’s determination that 14 claims of a patented antibiotic are invalid, but a dissenting judge argued that the Federal Circuit has led district courts “into error” by issuing “inconsistent treatment of the procedures and burdens in applying the evidentiary factors of obviousness” (Merck Sharp & Dohme Corp. v. Hospira Inc., No. 17-1115, Fed. Cir., 2017 U.S. App. LEXIS 21201)....